Equities

Bellevue Life Sciences Acquisition Corp

BLAC:NAQ

Bellevue Life Sciences Acquisition Corp

Actions
FinancialsOpen End and Miscellaneous Investment Vehicles
  • Price (USD)11.05
  • Today's Change0.00 / 0.00%
  • Shares traded26.00
  • 1 Year change+5.34%
  • Beta--
Data delayed at least 15 minutes, as of Nov 05 2024 19:14 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, cash reserves at Bellevue Life Sciences Acquisition Corp fell by 109.08k. Cash Flow from Financing totalled 34.54m or -- of revenues. In addition the company used 818.77k for operations while cash used for investing totalled 33.83m.
Cash flow per share--
Price/Cash flow per share--
Book value per share2.69
Tangible book value per share2.69
More ▼

Balance sheet in USDView more

Bellevue Life Sciences Acquisition Corp has a Debt to Total Capital ratio of 9.00%.
Current ratio0.0488
Quick ratio--
Total debt/total equity0.0989
Total debt/total capital0.09
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.